Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02555150 · ClinicalTrials.gov registry record · Phase 3
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
A Phase 3 study, sponsored by Rhodes Pharmaceuticals, L.P..
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT02555150: Completed Phase 3 study, sponsored by Rhodes Pharmaceuticals, L.P..
NCT02555150 is a Phase 3 study that has completed, run by Rhodes Pharmaceuticals, L.P.. The registered enrollment target is 40 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02555150, a Phase 3 study, has completed, sponsored by Rhodes Pharmaceuticals, L.P..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this randomized, double-blind, crossover study is to compare two long-acting stimulant formulations-once-daily PRC-063 and once-daily lisdexamfetamine (LDX)-through a 15-hour period on driving performance, as measured with a driving simulator, in adult patients with ADHD.
Primary Outcome
The primary outcome measure will be the Tactical Driving Quotient (TDQ) between treatments. The TDQ is an accumulative effect size across multiple driving variables collected during the driving simulation, including: summed standard deviations of steering, driving off the road, veering across the midline, inappropriate braking while on the open road, missed stop signs, exceeding speed limit, standard deviation of speed, time at stop sign deciding when to turn left and time to complete left turn
Interventions
- DRUG Placebo
- DRUG lisdexamfetamine dimesylate
- DRUG PRC-063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
What the finished NCT02555150 record still lists
NCT02555150 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02555150 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02555150 about?
NCT02555150 is a clinical study titled "A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD". The purpose of this randomized, double-blind, crossover study is to compare two long-acting stimulant formulations-once-daily PRC-063 and once-daily lisdexamfetamine (LDX)-through a 15-hour period on driving performance, as measured with a driving simulator, in adult patients with ADHD.
What is the current status of trial NCT02555150?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2015-09. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02555150?
The interventions under investigation include: Placebo (DRUG), lisdexamfetamine dimesylate (DRUG), PRC-063 (DRUG).
Who is sponsoring clinical trial NCT02555150?
This trial is sponsored by Rhodes Pharmaceuticals, L.P., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02555150's enrollment target sits among peer trials
40 1878th of 2000 higher than 103 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia